CRBU - CIK 0001619856
Caribou Biosciences, Inc. trades as CRBU. In its fiscal 2025 annual report the company posted revenue of $11.16M, up 11.7% from the prior year and net income of -$148.13M. This page tracks Caribou Biosciences, Inc. through 317 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 6 fiscal years Caribou Biosciences, Inc.'s revenue grew from $5.79M to $11.16M, a compound annual growth rate of 11.6%. Net profit margin compressed from -404.8% to -1327.4% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| DEFR14A | - | 2026-05-01 |
| Annual report to shareholders | ARS | 2026-04-24 |
| Proxy materials | DEFA14A | 2026-04-24 |
| Proxy statement | DEF 14A | 2026-04-24 |
| PRE 14A | - | 2026-04-10 |
| Major company event | 8-K | 2026-03-31 |
The largest companies sharing Caribou Biosciences, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Caribou Biosciences, Inc. reported revenue of $11.16M for fiscal year 2025, an increase of 11.7% year over year.
In its latest fiscal year Caribou Biosciences, Inc. reported a net loss of $148.13M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.